Priorities for Antiretroviral Therapy Research in Sub-Saharan Africa: A 2002 Consensus Conference in Zambia

Background: A consensus conference was held to discuss priorities for antiretroviral therapy (ART) research in Zambia, one of the world's most heavily HIV-afflicted nations. Zambia, like other resource-limited settings, has increasing access to highly active antiretroviral therapy (HAART) because of declining drug costs, use of government-purchased generic medications, and increased global donations. For sustained delivery of care with HAART in a resource-constrained medical and public health context, operational research is required and clinical trials are desirable. The priority areas for research are most relevant today given the increasing availability of HAART. Methods: A conference was held in Lusaka, Zambia, in January 2002 to discuss priority areas for ART research in Zambia, with participants drawn from a broad cross section of Zambian society. State-of-the-art reviews and 6 intensive small group discussions helped to formulate a suggested research agenda. Results: Conference participants believed that the most urgent research priorities were to assess how therapeutic resources could be applied for the greatest overall benefit and to minimize the impact of nonadherence and viral resistance. Identified research priorities were as follows:To determine when to initiate HAART in relation to CD4+ cell countTo assess whether HIV/AIDS can be managed well without the use of costly frequent viral load measurements and CD4+ cell count monitoringTo assess whether HIV/AIDS can be managed in the same fashion in patients coinfected with opportunistic infections such as tuberculosis and HIV-related chronic diarrhea, taking into consideration complications that may occur in tuberculosis such as immune reconstitution syndrome and medication malabsorption in the presence of diarrheaTo carefully assess and characterize toxicities, adverse effects, and viral resistance patterns in Zambia, including studies of mothers exposed to prepartum single-dose nevirapineTo conduct operational research to assess clinical and field-based strategies to maximize adherence for better outcomes of ART in ZambiaTo assess ART approaches most valuable for pediatric and adolescent patients in Zambia Conference participants recommended that HIV-related clinical care and research be integrated within home-based care services and operated within the existing health delivery structures to ensure sustainability, reduce costs, and strengthen the structures. Conclusion: Our consensus was that antiretroviral clinical trials and operational research are essential for Zambia to address the new challenges arising from increasing ART availability. There is global consensus that antiretroviral clinical trials in resource-constrained countries are possible, and the capacity for such trials should be developed further in Africa.

[1]  R. Wood,et al.  Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study , 2002, The Lancet.

[2]  D. Bangsberg,et al.  Adherence is not a barrier to successful antiretroviral therapy in South Africa , 2003, AIDS.

[3]  Paul Farmer,et al.  Community-based approaches to HIV treatment in resource-poor settings , 2001, The Lancet.

[4]  R. Smego,et al.  Paradoxical tuberculous reactions in HIV-infected patients. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  J. Stringer,et al.  Cost‐Effective Use of Nevirapine to Prevent Vertical HIV Transmission in Sub‐Saharan Africa , 2000, Journal of acquired immune deficiency syndromes.

[6]  Andrew N. Phillips,et al.  When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study , 2001, AIDS.

[7]  T. Flanigan,et al.  Total Lymphocyte Count (TLC) Is a Useful Tool for the Timing of Opportunistic Infection Prophylaxis in India and Other Resource‐Constrained Countries , 2002, Journal of acquired immune deficiency syndromes.

[8]  Edward P Acosta,et al.  Comparison of Two Strategies for Administering Nevirapine to Prevent Perinatal HIV Transmission in High-Prevalence, Resource-Poor Settings , 2003, Journal of acquired immune deficiency syndromes.

[9]  M. Monze,et al.  Declining HIV prevalence and risk behaviours in Zambia: evidence from surveillance and population-based surveys , 2001, AIDS.

[10]  B. Amadi,et al.  Morbidity and nutritional impairment in relation to CD4 count in a Zambian population with high HIV prevalence. , 2002, Acta tropica.

[11]  D. Bangsberg,et al.  Doubts about DOT: antiretroviral therapy for resource‐poor countries , 2003, AIDS.

[12]  A. Harries,et al.  Preventing antiretroviral anarchy in sub-Saharan Africa , 2001, The Lancet.

[13]  P. Piot,et al.  International response to the HIV/AIDS epidemic: planning for success. , 2001, Bulletin of the World Health Organization.

[14]  S. Mitarai,et al.  Emergence of new HIV-1 subtypes other than Subtype C among antenatal women in Lusaka, Zambia. , 2001, AIDS research and human retroviruses.

[15]  Max Essex,et al.  Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in Botswana , 2003, Journal of acquired immune deficiency syndromes.

[16]  S. Vermund,et al.  Prevention of mother‐to‐child transmission of HIV in Africa: successes and challenges in scaling‐up a nevirapine‐based program in Lusaka, Zambia , 2003, AIDS.